Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,267,586	$ 4,068,950	$ 3,834,204
United States
Disaggregation of Revenue [Line Items]
Total revenues	3,831,598	3,660,109	3,489,977
Europe
Disaggregation of Revenue [Line Items]
Total revenues	341,122	312,706	269,243
All other
Disaggregation of Revenue [Line Items]
Total revenues	94,866	96,135	74,984
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	4,021,849	3,821,164	3,736,943
Total Neuroscience
Disaggregation of Revenue [Line Items]
Total revenues	2,878,494	2,698,318	2,707,843
Xywav
Disaggregation of Revenue [Line Items]
Total revenues	1,656,986	1,473,202	1,272,977
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	146,034	233,816	569,730
Epidiolex/Epidyolex
Disaggregation of Revenue [Line Items]
Total revenues	1,059,197	972,423	845,468
Sativex
Disaggregation of Revenue [Line Items]
Total revenues	16,277	18,877	19,668
Total Oncology
Disaggregation of Revenue [Line Items]
Total revenues	1,129,183	1,111,375	1,015,254
Rylaze/Enrylaze
Disaggregation of Revenue [Line Items]
Total revenues	402,920	410,846	394,226
Zepzelca
Disaggregation of Revenue [Line Items]
Total revenues	307,309	320,318	289,533
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	199,392	216,565	184,000
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	146,709	162,595	147,495
Modeyso
Disaggregation of Revenue [Line Items]
Total revenues	48,043	0	0
Ziihera
Disaggregation of Revenue [Line Items]
Total revenues	24,810	1,051	0
Other
Disaggregation of Revenue [Line Items]
Total revenues	14,172	11,471	13,846
High-sodium oxybate AG royalty revenue
Disaggregation of Revenue [Line Items]
Total revenues	211,725	217,575	75,918
Other royalty and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 34,012	$ 30,211	$ 21,343